Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (JPRN-jRCT2031250419) titled 'A Study of ZW251 in Participants With Advanced Solid Tumors' on Oct. 8.
Study Type: Interventional
Study Design:
single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose
Primary Sponsor: Tsutsui Toshio
Condition:
Advanced Solid Tumors, Including Hepatocellular Carcinoma
Intervention:
In Part 1 (dose escalation), ZW251 will be administered intravenously once every 21 days (Q3W). Approximately 6 dose levels are expected as follows: Level 1: 3.2 mg/kg, Level 2: 6.4 mg/kg, Level 3: 9.6 mg/kg, Level 4: 12.8 mg/kg, Level 5: 16 mg/kg, Level 6: 19.2 mg/kg. In Part 2 (...